Pathophysiological and clinical approach to cirrhotic cardiomyopathy

Journal of Gastrointestinal and Liver Diseases

Volumn 23, Issue 3, 2014, Pages 301-310

  Páll, Alida ^a   Czifra, Árpád ^a   Vitális, Zsuzsanna ^a   Papp, Mária ^a   Paragh, György ^a   Szabó, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Arrhythmias; Cardiomyopathy; Heart failure; Liver cirrhosis

Indexed keywords

ACTION POTENTIAL; ANIMAL; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; COMPLICATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONDUCTION SYSTEM; HEART VENTRICLE; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; HEART CONDUCTION SYSTEM; HEART VENTRICLES; HEMODYNAMICS; HUMANS; LIVER CIRRHOSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84906849813     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.1543/jgld.2014.1121     Document Type: Review

References (97)

1. Henriksen JH, Moller S. Cardiac and systemic haemodynamic complications of liver cirrhosis. Scand Cardiovasc J 2009;43:218-225.
2. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009;3:294-304.
3. Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010;56:539-549.
4. Mikulic E, Munoz C, Puntoni LE, Lebrec D. Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis. Clin Pharmacol Ther 1983;34:56-59.
5. Fitzgibbons TP, Meyer TE, Aurigemma GP. Mortality in diastolic heart failure: an update. Cardiol Rev 2009;17:51-55.
6. Rosenberg MA, Manning WJ. Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circulation 2012;126:2353-2362.
7. Torregrosa M, Aguade S, Dos L, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42:68-74.
8. Moller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol 2013;167:1101-1108.
9. Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J 2009;85:44-54.
10. Henriksen JH, Siemssen O, Krintel JJ, Malchow-Moller A, Bendtsen F, Ring-Larsen H. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. J Hepatol. 2001;34:53-60.
11. Schrier RW, Ecder T. Gibbs memorial lecture. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis. Mt Sinai J Med 2001;68:350-361.
12. Moller S, Henriksen JH, Bendtsen F. Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol 2003;284:G970-G979.
13. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000;118:937-944.
14. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005;146:315-323.
15. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43(2 Suppl 1):S121-S131.
16. Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006;119(7 Suppl 1):S47-S53.
17. Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008;57:268-278.
18. Bernardi M. Cirrhotic cardiomyopathy. Clin Liver Dis 2013;2:99-101.
19. Krag A, Bendtsen F, Mortensen C, Henriksen JH, Moller S. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. Eur J Gastroenterol Hepatol 2010;22:1085-1092.
20. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000;(4 Suppl 1):S44-S52.
21. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46:935-946.
22. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J 2008;84:662-670.
23. Ceolotto G, Papparella I, Sticca A, et al. An abnormal gene expression of the beta-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats. Hepatology 2008;48:1913-1923.
24. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol 1997;26:904-912.
25. Szabo Z, Harangi M, Lorincz I, et al. Effect of hyperlipidemia on QT dispersion in patients without ischemic heart disease. Can J Cardiol 2005;21:847-850.
26. Anselmi A, Gaudino M, Baldi A, et al. Role of apoptosis in pressureoverload cardiomyopathy. J Cardiovasc Med (Hagerstown) 2008;9:227-232.
27. Herring N, Danson EJF, Paterson DJ. Cholinergic control of heart rate by nitric oxide is site specific. News Physiol Sci 2002;17:202-206.
28. Finucci G, Desideri A, Sacerdoti D, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996;31:279-284.
29. Patel BM, Mehta AA. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. Eur J Pharmacol 2012;697:1-12.
30. Gundling F, Schmidtler F, Zelihic E, et al. Frequency of cardiac arrhythmia in patients with liver cirrhoses and evaluation of associated factors. Z Gastroenterol 2012;50:1149-1155.
31. Rigolli M, Whalley GA. Heart failure with preserved ejection fraction. J Geriatr Cardiol 2013;10:369-376.
32. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34.
33. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002;36:513-520.
34. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006;44:994-1002.
35. Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet 1993;341:1423-1428.
36. Lazzeri C, La Villa G, Laffi G, et al. Autonomic regulation of heart rate and QT interval in nonalcoholic cirrhosis with ascites. Digestion 1997;58:580-586.
37. Bernardi M, Rubboli A, Trevisani F, et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol 1991;12:207-216.
38. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol 2006;17:333-336.
39. Lorincz I, Kun C, Szabo Z. QT dispersion -clinical significance -past, present, future. Acta Physiol Hung 2002;89:138.
40. Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000;36:1749-1766.
41. Meyer JS, Mehdirad A, Salem BI, Kulikowska A, Kulikowski P. Sudden arrhythmia death syndrome: importance of the long QT syndrome. Am Fam Physician 2003;68:483-488.
42. Baik SK, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Orphanet J Rare Dis 2007;2:15.
43. Trevisani F, Merli M, Savelli F, et al. QT interval in patients with noncirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 2003;38:461-467.
44. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997;273:G537-G544.
45. Ward CA, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology 2001;121:1209-1218.
46. Antzelevitch C, Shimizu W, Yan GX, Sicouri S. Cellular basis for QT dispersion. J Electrocardiol 1998;30 Suppl:168-175.
47. Moreau R, Komeichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphatesensitive potassium channels in rats with cirrhosis. Gastroenterology 1994;106:1016-1023.
48. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999;104:1223-1233.
49. Wiese S, Mortensen C, Gotze JP, et al. Cardiac and proinflammatory markers predict prognosis in cirrhosis. Liver Int 2013 Dec 7.
50. Salter KJ, Kozlowski RZ. Differential electrophysiological actions of endothelin-1 on Cl-and K+ currents in myocytes isolated from aorta, basilar and pulmonary artery. J Pharmacol Exp Ther 1998;284:1122-1231.
51. Henriksen JH, Bendtsen F, Hansen EF, Moller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted. J Hepatol 2004;40:239-246.
52. Zambruni A, Trevisani F, Di Micoli A, et al. Effect of chronic betablockade on QT interval in patients with liver cirrhosis. J Hepatol 2008;48:415-421.
53. Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997;26:1131-1137.
54. Rector WG Jr, Adair O, Hossack KF, Rainguet S. Atrial volume in cirrhosis: relationship to blood volume and plasma concentration of atrial natriuretic factor. Gastroenterology 1990;99:766-770.
55. Gerbes AL, Wernze H, Arendt RM, Riedel A, Sauerbruch T, Paumgartner G. Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. Hepatology 1989;9:417-422.
56. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond) 2001;101:621-628.
57. Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-1517.
58. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009;191:341-366.
59. Pateron D, Beyne P, Laperche T, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999;29:640-643.
60. Wanninger J, Weigert J, Wiest R, et al. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine 2011;55:435-440.
61. Curtis JP, Sokol SI, Wang Y, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003;42:736-742.
62. Wilson DJ, North N, Wilson RA. Comparison of Left Ventricular Ejection Fraction Calculation Methods. Echocardiography 1998;15:709-712.
63. Otterstad JE. Measuring left ventricular volume and ejection fraction with the biplane Simpson's method. Heart 2002;88:559-560.
64. Mondillo S, Galderisi M, Mele D, et al. Speckle-tracking echocardiography: a new technique for assessing myocardial function. J Ultrasound Med 2011;30:71-83.
65. Ishibashi M, Yoshioka F, Umezaki N, Morita S. Assessment of cardiac function using radionuclide techniques--theory, technical considerations and clinical application. Kurume Med J 1991;38:93-107.
66. Little WC, Warner JG Jr, Rankin KM, Kitzman DW, Cheng CP. Evaluation of left ventricular diastolic function from the pattern of left ventricular filling. Clin Cardiol 1998;21:5-9.
67. Denes M, Kiss I, Lengyel M. Assessment of diastolic dysfunction in elderly hypertensive patients using integrated Doppler echocardiography. Blood Press 2009;18:135-141.
68. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165-193.
69. Gilotra NA, Chow GV, Cingolani OH. Cardiac amyloidosis presenting with prolonged QT interval and recurrent polymorphic ventricular tachycardia. Tex Heart Inst J 2013;40:193-195.
70. Uyarel H, Uslu N, Okmen E, et al. QT dispersion in sarcoidosis. Chest 2005;128:2619-2625.
71. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart 2004;90:1224-1228.
72. Lee NR, Park JH, Rhee KS. Acquired long QT syndrome and sudden cardiac death due to secondary hemochromatosis with multitransfusions for severe aplastic anemia. Ann Hematol 2008;87:933-935.
73. Cardoso C, Salles G, Bloch K, Deccache W, Siqueira-Filho AG. Clinical determinants of increased QT dispersion in patients with diabetes mellitus. Int J Cardiol 2001;79:253-262.
74. Ishizaki F, Harada T, Yoshinaga H, Nakayama T, Yamamura Y, Nakamura S. Prolonged QTc intervals in Parkinson's disease -relation to sudden death and autonomic dysfunction. No To Shinkei 1996;48:443-448.
75. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. BMJ 2000;320:1158-1159.
76. Panicker GK, Karnad DR, Joshi R, et al. Z-score for benchmarking reader competence in a central ECG laboratory. Ann Noninvasive Electrocardiol 2009;14:19-25.
77. Panicker GK, Karnad DR, Natekar M, Kothari S, Narula D, Lokhandwala Y. Intra-and interreader variability in QT interval measurement by tangent and threshold methods in a central electrocardiogram laboratory. J Electrocardiol 2009;42:348-352.
78. Bazett HC. An analysis of the time-relations of electrocardiograms. Ann Noninvasive Electrocardiol 1997;2:177-194.
79. QTc Prolongation and Risk of Sudden Cardiac Death: Is the Debate Over? Medscape. 2006 Feb 3; http://www.medscape.com/ viewarticle/522879.
80. Moller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J 2013;34:2804-2811.
81. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-e239.
82. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012;56:1983-1992.
83. Wong F, Liu P, Blendis L. The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. Hepatology 2002;35:1449-1458.
84. Bos R, Mougenot N, Findji L, Mediani O, Vanhoutte PM, Lechat P. Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. J Cardiovasc Pharmacol 2005;45:8-13.
85. Schrier RW. Use of diuretics in heart failure and cirrhosis. Semin Nephrol 2011;31:503-512.
86. Vizzardi E, D'Aloia A, Giubbini R, et al. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol 2010;106:1292-1296.
87. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
88. Butler J, Ezekowitz JA, Collins SP, et al. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail 2012;18:265-281.
89. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol 1997;26:904-912.
90. Bosch J. Carvedilol: the beta-blocker of choice for portal hypertension? Gut 2013;62:1529-1530.
91. Barrese V, Taglialatela M. New advances in beta-blocker therapy in heart failure. Front Physiol 2013;4:323.
92. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999;33:916-923.
93. Cazzaniga M, Salerno F, Pagnozzi G, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007;56:869-875.
94. Shin WJ, Kim YK, Song JG, et al. Alterations in QT interval in patients undergoing living donor liver transplantation. Transplant Proc 2011;43:170-173.
95. Moller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001;36:785-794.
96. Hsu RB, Chang CI, Lin FY, et al. Heart transplantation in patients with liver cirrhosis. Eur J Cardiothorac Surg 2008;34:307-312.
97. Fiorucci S, Antonelli E, Brancaleone V, et al. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol 2003;39:932-939